University of Wisconsin, Madison

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Wisconsin, Madison sits in the top decile of US sponsors by registered trial count (#31 of 15,742 sponsors by registered trial count).

1,039 total trials 151 currently recruiting 712 completed early-phase tilt top decile by trial count

University of Wisconsin, Madison: 1,039 sponsored US clinical trials, 151 recruiting.

University of Wisconsin, Madison sponsors 1,039 registered US clinical trials on ClinicalTrials.gov, 151 of them currently recruiting, and 712 completed. 98 of these trials are in Phase 3-4 (later-stage) and 251 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 10 trials.

Top-decile sponsor footprint

University of Wisconsin, Madison ranks in the top decile of sponsors by registered trial count (#31 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

712 of 824 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,039 total, page 11 of 21

COMPLETED NA

The Metabolic Response to Reduced Branched-chain Amino Acids in Humans

NCT03239717

COMPLETED NA

Modeling Mood Course to Detect Markers of Effective Adaptive Interventions

NCT03358238

TERMINATED Phase 2

PSMA PET and MRI in Gynecological Cancers

NCT03302156

COMPLETED Phase 4

UW Quitting Using Intensive Treatment Study (QUITS)

NCT03176784

COMPLETED NA

Teachers and Parents as Partners During Middle School

NCT03298724

COMPLETED Phase 2

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

NCT03301350

COMPLETED

Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma

NCT03356470

COMPLETED

Yale Swallow Protocol in Extubated Patients

NCT03352908

TERMINATED Phase 4

Enhanced Recovery Strategies in Elective Breast Surgery

NCT03187080

COMPLETED NA

Young Adult Hypertension Self-Management Clinical Trial

NCT03158051

TERMINATED Phase 2

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

NCT03311126

COMPLETED NA

Cardiac Function and Metabolism in Young Adults Born Premature (PET-MRI)

NCT03245723

COMPLETED Phase 2

Ixazomib for Desensitization

NCT03213158

TERMINATED

Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR)

NCT04095091

TERMINATED

PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning

NCT03286972

COMPLETED

Survivorship Care Plans in a Community Oncology Practice

NCT03028584

COMPLETED

Improving the Assessment of Hypersomnolence

NCT02884505

TERMINATED Phase 1

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

NCT02943733

COMPLETED Phase 4

UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study

NCT03284307

TERMINATED Phase 2

A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer

NCT03186937

COMPLETED

Patterns of Neurocircuitry Activation In Severe Asthma

NCT03230188

COMPLETED NA

A Communication Tool to Assist Severely Injured Older Adults

NCT03188055

COMPLETED NA

C-arm Cone Beam CT Perfusion Guided Cerebrovascular Interventions

NCT03232151

COMPLETED NA

Strategies to Assist With Management of Pain

NCT03115359

COMPLETED NA

Cadence Modulation to Improve Well-Being, Kinematics and Aerobic Performance in Cyclists

NCT03482726

COMPLETED

Resident Wellness Initiative: Improving Physical Activity, Nutrition Education and Mental Health of Residents

NCT03183687

COMPLETED NA

Adaptation of a Health Promotion Nutrition Program for Older Adults

NCT03205007

TERMINATED Phase 4

Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty

NCT03182933

COMPLETED NA

Impact of Probiotic Use on Immune Cell Function in Children

NCT02687503

COMPLETED

Farms, Animals and Adolescents: Reinforcing the Microbiome

NCT03189849

TERMINATED Phase 2

Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

NCT02720185

COMPLETED Phase 2

Platelet-Rich Plasma Therapy for Patellar Tendinopathy

NCT03136965

COMPLETED NA

Community-Based Continence Promotion: Sustaining Healthy Aging in Place (SHAIP) Through Mind Over Matter (MOM)

NCT03140852

COMPLETED Phase 2

Testing Doxazosin to Treat Stress Mechanisms in Alcoholism

NCT02989493

COMPLETED Phase 4

Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

NCT02966314

COMPLETED NA

Postpartum Hypertension: Remote Patient Monitoring

NCT03111095

COMPLETED

Examining Prison Inmates' Attitudes and Internal Emotional States

NCT04374357

TERMINATED NA

Group vs. Traditional Diabetes Prenatal Care

NCT03080337

COMPLETED NA

Study: Diet and Exercise Study to Improve Brain Blood Flow: Blood Flow Improvement Trial

NCT03117829

COMPLETED

The "ToPIC" Study = Tool to Improve Participation In Clinical Trials

NCT03656276

COMPLETED NA

Parent-Mediated Intervention for Families With Children With Autism and Feeding Challenges

NCT03071120

COMPLETED Early Phase 1

PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

NCT03232164

COMPLETED

Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation

NCT02791568

COMPLETED Phase 1

Mechanisms of Cerebrovascular Control

NCT02936687

COMPLETED NA

Tobacco Pilot Study for Low Income Smokers

NCT03017092

COMPLETED Phase 2

PEAK Platelet Rich Plasma Injection Treatment for Chronic Lateral Epicondylosis

NCT03072381

COMPLETED NA

Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery

NCT02955043

COMPLETED NA

Promoting Self-Regulation Skills and Healthy Eating Habits in Early Head Start

NCT03958214

COMPLETED Phase 1

Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

NCT02966340

COMPLETED NA

Disseminating and Implementing a Smoking Cessation Program for Pregnant and Postpartum Women

NCT02952703

← Previous Page 11 of 21 Next →

Phase Distribution

PhaseTrial count
Phase 1 109
Phase 2 142
Phase 3 19
Phase 4 79

What is open in the University of Wisconsin, Madison pipeline

151 recruiting of 1,039 indexed (15% open); 712 completed (69%).

Phase mix: 98 late (III/IV) vs 251 early (I/II) (early-phase heavy).

Top condition: Healthy (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Wisconsin, Madison: open-pipeline peers nationwide

Peers matched on 1,039 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

University of Wisconsin, Madison sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 6%8%10%12%14%16% Total trials Recruiting share University of Wisconsin, MadisonUniversity of WashingtonBristol-Myers SquibbUniversity of FloridaUniversity of North Carolina, Chapel HillMasonic Cancer Center, University of MinnesotaModernaTXUnited States Naval Medical Center, San DiegoThe Cleveland Clinic
University of Wisconsin, Madison sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Wisconsin, Madison sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,039 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this University of Wisconsin, Madison page

1,039 registered trials is a research-attention snapshot, not an endorsement of University of Wisconsin, Madison or any single study.

  • 151 of University of Wisconsin, Madison's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition University of Wisconsin, Madison studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Wisconsin, Madison pipeline card: 1,039 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.